The hematopoietic growth factors in acute leukemia: US perspective

Cancer Treatment and Research

Volumn 157, Issue , 2011, Pages 307-337

  Frankfurt, Olga ^a   Tallman, Martin S ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; ANTHRACYCLINE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ELTROMBOPAG; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MAXY 34; MITOXANTRONE; PALIFERMIN; PLACEBO; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 13; RECOMBINANT INTERLEUKIN 3; RECOMBINANT INTERLEUKIN 5; RECOMBINANT STEM CELL FACTOR; REPIFERMIN; ROMIPLOSTIM; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; DEGRANULATION; DELAYED HYPERSENSITIVITY; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG CLEARANCE; DRUG HALF LIFE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LENGTH OF STAY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MORTALITY; MOUTH DISEASE; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL GRANULE; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA; UPREGULATION;

ACUTE DISEASE; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; LEUKEMIA; UNITED STATES;

EID: 78349273591     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7073-2_18     Document Type: Review

References (102)

1. Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis. 2002;185(10):1490-501.
2. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol. 2007;14(1):3-8.
3. Welte K, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88(6):1907-29.
4. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78(11):2791-808.
5. Boneberg EM, et al. Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood. 2000;95(1):270-6.
6. Franzke A, et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood. 2003;102(2):734-9.
7. Solaroglu I, et al. A novel neuroprotectant granulocyte-colony stimulating factor. Stroke. 2006;37(4):1123-8.
8. Kirsch F, Kruger C, Schneider A. The receptor for granulocyte-colony stimulating factor (G-CSF) is expressed in radial glia during development of the nervous system. BMC Dev Biol. 2008;8:32.
9. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood. 1996;88(3):761-77.
10. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111(4):1767-72.
11. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354(19):2034-45.
12. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533-44.
13. Gil-Lamaignere C, et al. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191(7):1180-7.
14. Lieschke GJ, et al. Mice lacking granulocyte colony-stimulating factor have chronic neu-tropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994;84(6):1737-46.
15. Lieschke GJ, et al. Mice lacking both macrophage- and granulocyte-macrophage colony-stimulating factor have macrophages and coexistent osteopetrosis and severe lung disease. Blood. 1994;84(1):27-35.
16. Crawford J, et al. Reduction by granulocyte colony-stimulating factor of fever and neu-tropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164-70.
17. Dale DC. Neutrophil biology and the next generation of myeloid growth factors. J Natl Compr Canc Netw. 2009;7(1):92-8.
18. Holmes FA, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727-31.
19. Green MD, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosup-pressive chemotherapy. Ann Oncol. 2003;14(1):29-35.
20. Kubista E, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003;3(6):391-8.
21. Lane S, Crawford J, Kenealy M, Cull G. Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy. Blood. 2005;106:11.
22. DeFrees S, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology. 2006;16(9):833-43.
23. Doherty DH, et al. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjug Chem. 2005;16(5):1291-8.
24. Robinson SN, et al. Hematopoietic progenitor cell mobilization in mice by sustained delivery of granulocyte colony-stimulating factor. J Interferon Cytokine Res. 2005;25(8): 490-500.
25. Cox GN, et al. Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp Hematol. 2004;32(5):441-9.
26. Halpern W, et al. Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res. 2002;19(11):1720-9.
27. Erben U, Thiel E, Notter M. Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells. Cancer Res. 1999;59(12):2924-30.
28. Chadwick DE, et al. Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells. Leuk Lymphoma. 1993;11(3-4):249-62.
29. MacVittie TJ, et al. Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood. 2000;95(3):837-45.
30. Williams DE, Park LS. Hematopoietic effects of a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein. Cancer. 1991;67(10 Suppl):2705-7.
31. Vadhan-Raj S, et al. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood. 1995;86(6): 2098-105.
32. Lee AY, et al. A recombinant human G-CSF/GM-CSF fusion protein from E. coli showing colony stimulating activity on human bone marrow cells. Biotechnol Lett. 2003;25(3): 205-11.
33. Smith TJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19): 3187-205.
34. Baer MR, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100(4):1224-32.
35. Ohno R, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med. 1990;323(13):871-7.
36. Stone RM, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332(25):1671-7.
37. Dombret H, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332(25):1678-83.
38. Rowe JM, et al. A randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86(2):457-62.
39. Usuki K, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol. 2002;116(1): 103-12.
40. Harousseau JL, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol. 2000;18(4):780-7.
41. Moore JO, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulo-cyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood. 1997;89(3):780-8.
42. Estey EH. Growth factors in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(1):175-87.
43. Bennett CL, et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol. 1999;10(2):177-82.
44. Lu Z, Luo R, Erder H, et al. Cost impact of filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukemia. Blood. 1996;88(10, Suppl 1):209a.
45. Woronoff-Lemsi M, Demoly P, Arveux P. Cost-effectiveness analysis of GOELEM SA3, a randomized placebo-controlled protocol of GM-CSF for elderly patients with acute myeloid leukemia. Blood. 1997;90(10, Suppl 1):72a.
46. Bennett CL, et al. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Invest. 2001;19(6):603-10.
47. Pui CH, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med. 1997;336(25):1781-7.
48. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-62.
49. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med. 2003;349(8):727-9.
50. Hiddemann W, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol. 1992;19(2 Suppl 4):31-7.
51. Miyauchi J, et al. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood. 1989;73(5):1272-8.
52. Cannistra SA, et al. Simultaneous administration of granulocyte- macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991;5(3):230-8.
53. Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood. 1993;81(2):281-92.
54. Rutella S, et al. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. Exp Hematol. 2006;34(1):54-65.
55. Lowenberg B, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-52.
56. Lowenberg B, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90(8):2952-61.
57. Lofgren C, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol. 2004;124(4):474-80.
58. Thomas X, Raffoux E, De Botton S, Pautas C. Effect of priming with granulocyte- macrophage colony-stimulating factor (GM-CSF) in younger adults with newly diagnosed acute myeloid leukemia (AML): a trial by the Acute Leukemia French Association (ALFA) Group. Blood. 2005;106(11):530a. Abstract 1862.
59. Thomas X, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia. 1999;13(8):1214-20.
60. Rowe JM, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-85.
61. Takamatsu Y, et al. Remission induction by granulocyte colony-stimulating factor in hypoplastic acute myelogenous leukemia complicated by infection. A case report and review of the literature. Acta Haematol. 1998;99(4):224-30.
62. Ferrara F, et al. Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation. Br J Haematol. 1999;106(2):520-3.
63. Faderl S, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999;5(12):4041-7.
64. Faderl S, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003;102(2): 630-7.
65. Ohno R, et al. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group. Int J Hematol. 1993;58(1-2):73-81.
66. Larson RA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556-64.
67. Thomas X, et al. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Hematol J. 2004;5(5):384-94.
68. Holowiecki J, et al. G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk Lymphoma. 2002;43(2):315-25.
69. Ottmann OG, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood. 1995;86(2):444-50.
70. Ibarra M, Escoboza J, Lopez-Hernandez M. Neutrophil recovery time and adverse effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Rev Invest Clin. 1999;51(2):77-80.
71. Aglietta M, et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest. 1989;83(2):551-7.
72. Tsuchiya H, et al. Responses to granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF in Ph1-positive acute lymphoblastic leukemia with myeloid surface markers. Blood. 1991;77(2):411-13.
73. Wielenga JJ, et al. Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia. 1996;10(1):43-7.
74. Zwierzina H, et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulo-cyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodys-plastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19(11):1929-33.
75. Riccioni R, et al. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. Br J Haematol. 2009;144(3): 376-87.
76. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res. 2004;91:69-136.
77. Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351(25):2590-8.
78. Spencer A, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 2005;35(10):971-7.
79. Moroni E, et al. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res. 2002;11(1):19-32.
80. Blazar BR, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2006;108(9):3216-22.
81. Nasilowska-Adamska B, et al. The influence of palifermin (Kepivance) on oral mucosi-tis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant. 2007;40(10):983-8.
82. Langner S, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant. 2008;42(4):275-9.
83. van der Velden WJ, Herbers AH, Blijlevens NM. Palifermin in allogeneic HSCT: many questions remain. Bone Marrow Transplant. 2009;43(1):85-6.
84. Freytes CO, et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoi-etic stem cell transplantation. Clin Cancer Res. 2004;10(24):8318-24.
85. Archimbaud E, et al. A randomized, double-blind, placebo-controlled study with pegy-lated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94(11):3694-701.
86. Schiffer CA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95(8):2530-5.
87. Geissler K, et al. Prior and concurrent administration of recombinant human megakary-ocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol. 2003;82(11):677-83.
88. Basser RL, et al. Development of pancytopenia with neutralizing antibodies to thrombopoi-etin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99(7):2599-602.
89. Estey EH, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodys-plastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99(12):4343-9.
90. Ellis M, et al. Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361(9354):275-80.
91. Welte K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin- Frankfurt-Munster Study Group. Blood. 1996;87(8):3143-50.
92. Geissler K, et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - a randomized phase-III study. Blood. 1997;90(2):590-6.
93. Ifrah N, et al. Intensive short term therapy with granulocyte-macrophage- colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. Cancer. 1999;86(8):1496-505.
94. Heil G, et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia. 1995;9(1):3-9.
95. Zittoun R, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1996;14(7):2150-9.
96. Witz F, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1998;91(8):2722-30.
97. Hast R, et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia. 2003;17(9):1827-33.
98. Amadori S, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106(1):27-34.
99. Heil G, et al. A randomized, double-blind, placebo-controlled, phase III study of fil-grastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90(12):4710-8.
100. Godwin JE, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood. 1998;91(10):3607-15.
101. Bradstock K, et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia. 2001;15(9):1331-8.
102. Goldstone AH, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302-11.